

## 정신분열병 약물 치료에 대한 한국형 알고리즘의 개발 계획

안용민<sup>1</sup> · 강대엽<sup>2</sup> · 김승현<sup>3</sup> · 김창윤<sup>4</sup> · 심주철<sup>5</sup>  
 안석균<sup>6</sup> · 이중서<sup>7</sup> · 조현상<sup>6</sup> · 박원명<sup>8</sup> · 권준수<sup>1</sup>

서울대학교 의과대학 정신과학교실,<sup>1</sup> 용인정신병원 정신과,<sup>2</sup> 고려대학교 의과대학 신경정신과학교실,<sup>3</sup>  
 울산대학교 의과대학 정신과학교실,<sup>4</sup> ,<sup>5</sup>  
 ,<sup>6</sup> ,<sup>7</sup> 가 ,<sup>8</sup>

## ABSTRACT

### Designs and Methods for the Development of Korean Medication Algorithm for Schizophrenic Patients

Yong Min Ahn, MD,<sup>1</sup> Dae-Yeob Kang, MD,<sup>2</sup> Seung-Hyun Kim, MD,<sup>3</sup>  
 Chang Yoon Kim, MD,<sup>4</sup> Joo Cheol Shim, MD,<sup>5</sup> Suk Kyoan An, MD,<sup>6</sup>  
 Jung-Seo Yi, MD,<sup>7</sup> Hyun-Sang Cho, MD,<sup>6</sup>  
 Won-Myong Bahk, MD<sup>8</sup> and Jun Soo Kwon, MD<sup>1</sup>

<sup>1</sup>Department of Psychiatry, Seoul National University College of Medicine, Seoul,

<sup>2</sup>Department of Psychiatry, Yong-In Mental Hospital, Yongin,

<sup>3</sup>Department of Neuropsychiatry, College of Medicine, Korea University, Seoul,

<sup>4</sup>Department of Psychiatry, University of Ulsan, College of Medicine, Ulsan,

<sup>5</sup>Department of Neuropsychiatry, Medical College, and Institute of Neuroscience, Inje University, Seoul,

<sup>6</sup>Department of Psychiatry, College of Medicine, Yonsei University, Seoul,

<sup>7</sup>Department of Psychiatry, College of Medicine, Hallym University, Seoul,

<sup>8</sup>Department of Psychiatry, College of Medicine, Catholic University, Seoul, Korea

As a solution about many problems of pharmacotherapy for Korean patients with major psychiatric disorders, Korean Medication Algorithm Project for Major Psychiatric Disorders (KMAP) was launched. Recently, a medication algorithm for schizophrenic patients was developed and distributed. This review article showed the designs, processes and methods for developing this algorithm. Also we compared the development of Korean algorithm for schizophrenics with other foreign representative algorithms or clinical practice guidelines. We hope that this review elicit the productive criticism about the rigour, the system of development and the objectivity of content. The limitations and problems of Korean algorithm are also discussed in this review. (Korean J Psychopharmacol 2003;14(2):108-118)

**KEY WORDS** : Schizophrenia · Pharmacotherapy · Algorithm · Korean Medication Algorithm Project for Major Psychiatric Disorders.

2000 10 24

2001 3 30

교신저자 : , 110 - 799

28

: (02) 760 - 2457 · : (02) 744 - 7241 E - mail : kwonjs@plaza.snu.ac.kr

가 .<sup>1)</sup> 1994  
 ' United States Office of the Assistant Secretary  
 of Defense for Health Affairs ' Civilian Health and  
 Medical Program of the Uniformed Services(CHAMPUS)

### 외국의 대표적인 정신분열병 약물 치료 임상지침서와 알고리즘

가 ,  
<sup>2)</sup>  
 , 가  
 . 1990

<sup>5)</sup> Pa-  
 tient Outcome Research Team(PORT)  
 protocol,<sup>6,7)</sup> 가가 International  
 Psychopharmacology Algorithm Project(IPAP)  
<sup>8,9)</sup> 가  
 Expert Consensus Guideline Series for the  
 treatment of Schizophrenia,<sup>10,11)</sup>

가  
 가 .<sup>1)</sup>  
 가

Texas Medication  
 Algorithm Project(TMAP)  
<sup>12,13)</sup>  
 1 .<sup>13,14)</sup>  
 , 1990 , 1 ,

(Korean Medication Algorithm Project  
 for Major Psychiatric Disorders ; KMAP)  
<sup>1,3)</sup> KMAP  
 1 .<sup>1)</sup>

가 . 가  
 .

KMAP  
 2 .<sup>3)</sup> 2001 .<sup>1)</sup>  
 KMAP .<sup>4)</sup> 가

가  
 가  
 TMAP

가  
 KMAP  
<sup>12,13)</sup>

**Table 1.** Comparisons of Schizophrenia Medication Guidelines (modified from Milner & Valenstein, 2002 and Buckley et al. 1999)

	Expert consensus guideline Series	American psychiatric association	International psychopharmacology algorithm project	Patient outcome research team (PORT)	Texas medication algorithm project
Publication of last edition	1999	1997	1998	1998	1998
Methods of development	Formal consensus	Evidence based	Evidence based (+ formal consensus)	Evidence based	Evidence based (+ formal consensus)
Format	Table	Literature review	Algorithm	Numbered recommendation	Algorithm
Concise & easily operationalized	No	No	Yes	Yes	Yes
Nonmedication intervention specified	Yes	Yes	No	Yes	No
1st-line medication specified	Yes	Yes	Yes	No	Yes
1st-line atypical antipsychotics	All newer atypicals	Ris	Ris, Olz, Zot, Zip, Ser, Quet	Ris	Ris, Olz, Quet
1st-line typical antipsychotics	No	All	No <sup>1</sup>	All	No
Number of steps before clozapine	2	1 - 2	2 - 3	2	3 - 4
Number of steps after clozapine	Not consensus	0	0	1	2
Duration of treatment specified	Yes	Yes	Yes	Yes	Yes
Doses specified	Yes	Yes	Yes	Yes	Yes
Response criteria specified	No	No	No	No	Yes

\*All = All typical antipsychotics

\*Ris = risperidone, Olz = olanzapine, Zot = zotepine, Zip = ziprasidone, Ser = sertindole, Quet = quetiapine

<sup>1</sup>No typical antipsychotics except haloperidol injection (IM, IV) for severe psychotic symptoms

## 1. 미국 정신의학회의 임상지침서

1997년 5월, 미국정신의학회는 'Schizophrenia Medication Guidelines' (acute phase), (stabilization phase) (stable phase)를 발표하였다. 이 지침서는 총 7개의 단계로 구성되어 있으며, 총 581개의 약물 처방을 포함하고 있다. 이 지침서는 1990년 7월 15일 발표되었다.

## 2. Expert consensus guideline series의 임상지침서

3월, Expert Consensus Guideline Series가 발표되었다.



1994 가 2,18) 가 가  
 6,7) A, B C  
 6) 7) 1995  
 6) 1, 1998 7)  
 1 1 3

Series TDMHMR 가 가  
 2  
 feedback meeting  
 12) 3  
 20)  
 1 3

**5. TMAP의 알고리즘**  
 TMAP 1995 Texas Department of Mental Health and Mental Retardation(TDMHMR)

19) 가 KMAP  
 가 12,20)  
 가, 1, 2  
 가 가, 3  
 가 가 21)  
 가 가 가  
 가 가 12)  
 가 22)  
 Expert Consensus Guidelines Series  
 Expert Consensus Guideline

가 가  
 가 20)  
 KMAP  
**정신분열병의 약물 치료에 대한  
 한국형 알고리즘 개발 계획**  
 1. 한국형 알고리즘의 필요성  
 5 23,24)  
 3)  
 1) 진료 부분에서의 차이  
 가 가

가 . , (32,33)

가 . 가 . 1998 40 (34)

가 . 가 . 25)

가 . 212 ,

가 . 26) 27) 115 124

가 . 가 20 , 13

가 . 2 가 . 5

28) 239 ,

5,11,12) 25) , 72

33 ( 17 , 13

35)

가 . 29) 24

29) , 31.1%

가 . 가 가

6.9% 62.2%

가 가 가

가 가

3) 정책 및 진료 외적 요소의 차이

가 . 가 (36)

2) 연구 분야에서의 차이

가 . 가 ,

가 가 30)

31) 가 가 , 5 (2000 ) 3





가 (가, 1), 2  
 KMAP ( ), 3  
 TMAP ( ), 4  
 TMAP ( ) 5  
 KMAP 가  
 TMAP 가  
 TMAP KMAP 20)  
 TMAP KMAP 26 가

3) 3단계 : 시범 Site 적용을 통한(Field Trial을 통한)  
 '수정된 알고리즘'

1, 2 2001  
 AP 가  
 가  
 24  
 가

2) 2단계 : 공식적 합의를 통해 만들어진 알고리즘

1 50  
 가 가 1  
 2  
 57  
 87.7% 50  
 5 가  
 가  
 23 (3 )

4. 한국형 알고리즘의 주요 문제점

가 가  
 KMAP  
 가 3)  
 KMAP

가 2 가 1) 가  
10 50

가

가 가 가 1) 3)

가 가 가 결론

가 KMAP

16)

### 5. 개발 후의 계획 KMAP

1)

### 참고문헌

1) 안용민 · 김대진 · 권준수 · 박원명 · 이홍식 · 김용식. 주요

- 정신질환의 약물 치료에 대한 한국형 알고리즘 개발 (1) -알고리즘과 임상지침서의 장·단점 및 개발과 관련된 일반사항-. 대한정신약물학회지 2002;13:18-29.
- 2) CHAMPUS. *National Quality Management Project: Side-by-side comparison of Mental Health Practice Guidelines*. Beaverton: Science Applications International, 1994.
  - 3) 김대진·안용민·강대엽·김승현·김창윤·민경준 등. 주요정신질환의 약물 치료에 대한 한국형 알고리즘 개발 (2) -한국형 알고리즘 개발 사업내용과 기본계획, 조직구성, 알고리즘 개발의 기본원칙, 개발방법, 제한점 및 사용시 주의점-. 대한정신약물학회지 2002;13:30-36.
  - 4) 한국형 정신분열병. 양극성장애 약물치료 알고리즘 개발위원회. 정신분열병 약물치료에 대한 한국형 알고리즘 지침서, 2001.
  - 5) Herz MI, Liberman RP, Lieberman JA. *American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia*. *Am J Psychiatry* 1997;154(Suppl):1-63.
  - 6) Lehman AF, Carpenter WT Jr, Goldman HH, Steinwachs DM. *Treatment outcomes in Schizophrenia: Implication for practice, policy, and research*. *Schizophr Bull* 1995;24:669-675.
  - 7) Lehman AF, Steinwachs DM. *Co-investigators of the PORT Project. At issue: Translating Research into Practice: The Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations*. *Schizophr Bull* 1998;24:1-10.
  - 8) Zarate CA, Daniel DG, Kinon BJ, Litman RE, Naber D, Pickard D, et al. *Algorithms for the treatment of schizophrenia*. *Psychopharmacol Bull* 1995;31:461-467.
  - 9) Pearsall R, Glick ID, Pickard D, Suppes T, Tauscher J, Jobson KO. *A new algorithms for treating schizophrenia*. *Psychopharmacol Bull* 1998;34:349-353.
  - 10) Frances A, Docherty JP, Kahn DA. *The Expert Consensus Guideline Series. Treatment of Schizophrenia*. *J Clin Psychiatry* 1996;57(Suppl 1):1-59.
  - 11) McEvoy JP, Scheffler PL, Frances A. *The Expert Consensus Guideline Series. Treatment of Schizophrenia*. *J Clin Psychiatry* 1999;60(Suppl 11):1-80.
  - 12) Chiles JA, Miller AL, Crismon ML, Rush AJ, Krasnoff AS, Shon SS. *The Texas Medication Algorithm Project: Development and Implementation of the Schizophrenia Algorithm*. *Psychiatr Serv* 1999;50:69-74.
  - 13) Buckley PF, Miller A, Chiles JA, Sajatovic M. *Implementing effectiveness research and improving care for schizophrenia in real-world settings*. *Am J Manag Care* 1999;5:SP47-SP56.
  - 14) Milner KK, Valenstein M. *A comparison of Guidelines for the treatment of Schizophrenia*. *Psychiat Serv* 2002;53:888-890.
  - 15) Woolf SH. *Practice guidelines: a new reality in medicine, II: methods of developing guidelines*. *Arch Intern Med* 1992;152:946-952.
  - 16) Harpwood V. *Guidelines in medical practice. the legal issues*. *Cephalalgia*. 1998;18(suppl 21):56-62.
  - 17) Sato M, Higuchi T. *Pharmacotherapy algorithms*. *Psychiatry and Clinical Neurosciences* 1999;53:S1-S82.
  - 18) Drake RE, Goldman HH, Leff HS, Lehman AF, Dixon L, Mueser KT, et al. *Implementing evidence-based practices in routine mental health service settings*. *Psychiatr Serv* 2001;52:179-182.
  - 19) Shon SP, Toprac MG, Crismon ML, Rush AJ. *Strategies for implementing psychiatric medication algorithms in the public sector*. *J Pract Psychiatry Behav Health* 1999;5:32-36.
  - 20) Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP. *The Texas Medication Algorithm Project (TMAP) Schizophrenia Algorithms*. *J Clin Psychiatry* 1999; 60:649-657.
  - 21) Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SP, Suppes T, et al. *Medication treatment for the severely and persistently mentally ill: The Texas Medication Algorithm Project*. *J Clin Psychiatry* 1999;60:284-291.
  - 22) Randall G, Taylor DW. *Clinical practice guidelines: the need for improved implementation strategies*. *Health Manage Forum* 2000;13:36-42.
  - 23) Littjohns P, Cluzeau F, Bale R, Grimshaw J, Feder G, Moran S. *The quantity and quality of clinical guidelines for the management of depression in primary care in the UK*. *Br J Gen Pract* 1999;49:205-210.
  - 24) Cluzeau FA, Littlejohns P, Grimshaw JM, Feder G, Moran SE. *Development and application of a generic methodology to assess the quality of clinical guidelines*. *Int J Qual Health Care* 1999;11:21-28.
  - 25) 김병로·강윤형·홍경수·유병희·김승태. 정신분열병의 약물 유지치료 현황 서울, 경기 일원의 정신과 임상의학의 의견. *신경정신의학* 1997;36:43-54.
  - 26) Glaer WM, Kane JM. *Depot neuroleptic therapy: An underutilized treatment option*. *J Clin Psychiatry* 1992;53:426-433.
  - 27) Shen WW. *Pharmacotherapy of schizophrenia: The American current status*. *Keio J of Medicine* 1994;43:192-200.
  - 28) Johnson DAW, Wright NF. *Drug prescribing for schizophrenic outpatients on depot injections*. *Br J Psychiatry* 1990;156:827-834.
  - 29) 정성훈·안용민·김용식. 한국 RODOS 연구자 모임. 리스페리돈과 올란자핀 사용 패턴의 전국적 변이 조사. *신경정신의학* 2003;42:79-88.
  - 30) Poolsup N, Li Wan Po A, Knight TL. *Pharmacogenetics and psychopharmacotherapy*. *J Clin Pharm Ther* 2000;25:197-220.
  - 31) Dubertret C, Gorwood P, Ades J, Feingold J, Schwartz JC, Sokoloff P. *Meta-analysis of DRD3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasian*. *Am J Med Genet* 1998;81:318-322.
  - 32) Ruiz P, Varner RV, Small DR, Johnson BA. *Ethnic differences in the neuroleptic treatment of Schizophrenia*. *Psychiatr Q* 1999; 70:163-172.
  - 33) Matsuda KT, Cho MC, Lin KM, Smith MW, Young AS, Adams JA. *Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients*. *Psychopharmacol Bull* 1996;32:253-257.
  - 34) 김영훈·이홍식·장문정·정도윤. 국내 정신과 임상약물 연구: 1962~1998년. 대한정신약물학회지 2000;11:35-51.
  - 35) 권준수·박원명. 정신분열병과 양극성장애의 한국형 알고리즘. 2001년 대한정신약물학회 동계심포지움 2001.
  - 36) Gjerris A. *Sharing the responsibilities: the roles of the government*. *Int Clin Psychopharmacol* 1999;14(suppl 3):7-9.
  - 37) Smith TE, Docherty JP. *Standards of care and clinical algorithms for treating schizophrenia*. *Psychiatr Clin North Am* 1998;21:203-220.
  - 38) Kasper S. *How much do novel antipsychotics benefit the patients?* *Int Clin Psychopharmacol* 1998;13(Suppl 3):S71-77.
  - 39) Koshino Y. *Algorithm for treatment-refractory schizophrenia*. *Psychiatry Clin Neurosci* 1999;53(Suppl):S9-13.
  - 40) Rush AJ, Prein RF. *From scientific knowledge to clinical practice of psychopharmacology: can the gap be bridged?* *Psychopharmacol Bull* 1995;31:7-20.
  - 41) 권준수. 정신분열병 약물치료에 대한 한국형 알고리즘. 2001년 대한신경정신의학회 추계학술대회, 2001.
  - 42) Gilbert DA, Altshuler KZ, Rago WV, Shon SP, Crismon ML, Toprac MG, et al. *Texas Medication Algorithm Project: Definitions, Rationale, and Methods to Develop medication Algorithms*. *J Clin Psychiatry* 1998;59:345-351.